Therapeutics for COVID-19
SS Toussi, JL Hammond, BS Gerstenberger… - Nature …, 2023 - nature.com
Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …
(COVID-19) illness were available within a year of the pandemic being declared but there …
Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease
Abstract Coronavirus disease 2019 (COVID-19) is a global pandemic caused by SARS-CoV-
2 infection and is associated with both acute and chronic disorders affecting the nervous …
2 infection and is associated with both acute and chronic disorders affecting the nervous …
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic
The COVID-19 pandemic caused by the SARS-CoV-2 virus remains a global public health
crisis. Although widespread vaccination campaigns are underway, their efficacy is reduced …
crisis. Although widespread vaccination campaigns are underway, their efficacy is reduced …
Distinctive roles of furin and TMPRSS2 in SARS-CoV-2 infectivity
R Essalmani, J Jain, D Susan-Resiga… - Journal of …, 2022 - Am Soc Microbiol
The spike protein (S) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
directs infection of the lungs and other tissues following its binding to the angiotensin …
directs infection of the lungs and other tissues following its binding to the angiotensin …
Cardiovascular disease and COVID-19: a consensus paper from the ESC working group on coronary pathophysiology & microcirculation, ESC working group on …
E Cenko, L Badimon, R Bugiardini… - Cardiovascular …, 2021 - academic.oup.com
The cardiovascular system is significantly affected in coronavirus disease-19 (COVID-19).
Microvascular injury, endothelial dysfunction, and thrombosis resulting from viral infection or …
Microvascular injury, endothelial dysfunction, and thrombosis resulting from viral infection or …
SARS-CoV-2 antiviral therapy
The development of effective antiviral therapy for COVID-19 is critical for those awaiting
vaccination, as well as for those who do not respond robustly to vaccination. This review …
vaccination, as well as for those who do not respond robustly to vaccination. This review …
[HTML][HTML] Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets
M Farahani, Z Niknam, LM Amirabad… - Biomedicine & …, 2022 - Elsevier
Deciphering the molecular downstream consequences of severe acute respiratory
syndrome coronavirus (SARS-CoV)− 2 infection is important for a greater understanding of …
syndrome coronavirus (SARS-CoV)− 2 infection is important for a greater understanding of …
Oral antiviral treatments for COVID-19: opportunities and challenges
L Rahmah, SO Abarikwu, AG Arero, M Essouma… - Pharmacological …, 2022 - Springer
The use of antiviral COVID-19 medications can successfully inhibit SARS-CoV-2 replication
and prevent disease progression to a more severe form. However, the timing of antiviral …
and prevent disease progression to a more severe form. However, the timing of antiviral …
SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models
AZ Mykytyn, TI Breugem, MH Geurts, J Beumer… - Journal of …, 2023 - Am Soc Microbiol
ABSTRACT SARS-CoV-2 can enter cells after its spike protein is cleaved by either type II
transmembrane serine proteases (TTSPs), like TMPRSS2, or cathepsins. It is now widely …
transmembrane serine proteases (TTSPs), like TMPRSS2, or cathepsins. It is now widely …
An update of anti-viral treatment of COVID-19.
S ŞİMŞEK YAVUZ… - Turkish journal of …, 2021 - search.ebscohost.com
Background/aim: Currently there is not an effective antiviral treatment for COVID-19, but a
large number of drugs have been evaluated since the beginning of the pandemic, and many …
large number of drugs have been evaluated since the beginning of the pandemic, and many …